ConductScience.org, home

Paper6233249

The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.

King A and 2 others. J Antimicrob Chemother, 1984. Cited by 93 papers, by iCite.

Cite this record

ConductScience Library. The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid. Papers, record 6233249. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6233249

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.
PubMed
Journal
J Antimicrob Chemother
PubMed
Year
1984
PubMed
Publication types
Comparative Study, Journal Article
PubMed
Citations, by iCite
93
iCite
Relative citation ratio, by iCite
5
iCite
Revised in PubMed
2019-05-11
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1King AA
2Shannon KK
3Phillips II

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-Bacterial AgentsMajor topic
BacteriaMajor topic
Nalidixic AcidMajor topic
QuinolinesMajor topic
Ciprofloxacin
Drug Resistance, Microbial
Humans
Norfloxacin

Source PubMed

Download CSV of topics

Cited by30

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 93 citations.

PMIDTitleJournalYearIn PapersSource
40433982RecN and RecA orchestrate an ordered DNA supercompaction response following ciprofloxacin-induced DNA damage in Escherichia coli.Nucleic Acids Res2025https://conductscience.org/library/papers/40433982PubMed
40143055Ciprofloxacin-Loaded Spray-Dried Lactose Particles: Formulation Optimization and Antibacterial Efficacy.Pharmaceutics2025https://conductscience.org/library/papers/40143055PubMed
3960690Quinolones in vitro.Pharm Weekbl Sci1986https://conductscience.org/library/papers/3960690PubMed
3908074Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.Drugs1985https://conductscience.org/library/papers/3908074PubMed
3847273Comparative activity of the quinolones against anaerobic bacteria isolated at community hospitals.Antimicrob Agents Chemother1985https://conductscience.org/library/papers/3847273PubMed
3606077Effects of ciprofloxacin on eucaryotic pyrimidine nucleotide biosynthesis and cell growth.Antimicrob Agents Chemother1987https://conductscience.org/library/papers/3606077PubMed
36060764-Quinolone drugs affect cell cycle progression and function of human lymphocytes in vitro.Antimicrob Agents Chemother1987https://conductscience.org/library/papers/3606076PubMed
3515312Fluorinated quinolones. A review of their mode of action, antimicrobial activity, pharmacokinetics and clinical efficacy.Pharm Weekbl Sci1986https://conductscience.org/library/papers/3515312PubMed
3438150Influence of quinolones on throat- and faecal flora of healthy volunteers.Pharm Weekbl Sci1987https://conductscience.org/library/papers/3438150PubMed
3286517Efficacy and safety of ciprofloxacin in the treatment of UTIs and RTIs in patients affected by liver diseases.Infection1988https://conductscience.org/library/papers/3286517PubMed
3164989Ciprofloxacin therapy of experimental endocarditis caused by methicillin-susceptible or methicillin-resistant Staphylococcus aureus.Antimicrob Agents Chemother1988https://conductscience.org/library/papers/3164989PubMed
3159749Ciprofloxacin disk susceptibility tests: interpretive zone size standards for 5-microgram disks.J Clin Microbiol1985https://conductscience.org/library/papers/3159749PubMed
3159571Interaction between ciprofloxacin and tobramycin or azlocillin against multiresistant strains of Acinetobacter anitratum in vitro.Eur J Clin Microbiol1985https://conductscience.org/library/papers/3159571PubMed
3132381Comparative in vitro activity of the new quinolone fleroxacin (RO 23-6240).Eur J Clin Microbiol Infect Dis1988https://conductscience.org/library/papers/3132381PubMed
3129373The relative efficacies of tobramycin and ciprofloxacin against Pseudomonas aeruginosa in vitro and in normal and granulocytopenic mice.Infection1988https://conductscience.org/library/papers/3129373PubMed
3124739Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis.Antimicrob Agents Chemother1987https://conductscience.org/library/papers/3124739PubMed
3053126Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use.Drugs1988https://conductscience.org/library/papers/3053126PubMed
3015015Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts.Antimicrob Agents Chemother1986https://conductscience.org/library/papers/3015015PubMed
3013631Overview of clinical experience with ciprofloxacin.Eur J Clin Microbiol1986https://conductscience.org/library/papers/3013631PubMed
3000292The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.Antimicrob Agents Chemother1985https://conductscience.org/library/papers/3000292PubMed

See all 30 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/6233249

GET https://conductscience.org/api/papers/v1/6233249/cited_by?page=2